NXSL yields 30303.03% · PFE yields 6.13%● Live data
📍 NXSL pulled ahead of the other in Year 1
Combined, NXSL + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NXSL + PFE for your $10,000?
NexTech FAS Technologies, Inc. engages in the design, manufacture, sale, and servicing of high-precision coating systems and advanced metrology and automation solutions for the semiconductor and flat panel display (FPD) industries. It also involves in the development FAS-Coat, a patented extrusion coating technology for aka spinless coating, slot die coating, and slit coating in the manufacturing process of FPD substrates. The company's products include Altair for testing the repeatability of systems that detect particles on the surface of substrates; Aludra, a reticle inspection system that employs light scattering technology to infer the presence of particles on a semiconductor reticle; Orion, a reticle inspection system, which provides inspection for semiconductor reticles and photomasks; FPDStar, an optical inspection system for identifying and mapping pattern, particle, and processing defects on FPD/TFT substrates; and NexTStar, an automated optical inspection system that represents breakthrough performance in FPD pattern, particle, and processing defect detection. Its products also comprise Pegasu, a wafer sorter series that provides standards-compliant user and automation interfaces; Proteus Reticle Load Port Upgrade kit, a hardware and software solution; and PST upgrades for wafer sorters. In addition, the company's FAS-Coat coating systems process substrates for the flat panel display, multi-chip module, solar cell, biomedical, and semiconductor industries. It was formerly known as NexTech Solutions, Inc. and changed its name to NexTech FAS Technologies, Inc. in July 2007. The company is headquartered in Austin, Texas.
Full NXSL Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.